Form 4: Guardant Health Director Tariq Musa Converts RSUs

Guardant Health Director Tariq Musa converted 249 restricted stock units into common stock on March 15, 2026, as part of a pre-scheduled vesting.

Summary

• Tariq Musa, a Director at Guardant Health, Inc. (GH), acquired 249 shares of common stock.
• This acquisition resulted from the conversion of restricted stock units (RSUs) on March 15, 2026.
• The transaction price for the acquired shares was $0.
• Following this transaction, Tariq Musa directly owns 8,742 shares of common stock.
• Musa also directly owns 2,999 restricted stock units after this conversion.
• The RSUs were granted on March 6, 2023, with a four-year vesting schedule.
• 25% of the award vested on March 15, 2024, and the remaining 75% vests monthly over the subsequent three years.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects a routine compensation event for a director, indicating continued alignment of interests without any immediate red flags or significant new developments.

Positives

• Director Tariq Musa continues to hold a significant number of common shares (8,742) and unvested restricted stock units (2,999), indicating ongoing alignment with shareholder interests.
• The transaction is a routine vesting event, reflecting a pre-established compensation plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU vesting are common in the biotech and healthcare sectors, reflecting standard executive compensation structures designed to align management incentives with long-term company performance. This particular filing does not provide specific insights into broader industry trends beyond standard compensation practices.

Comparison to Industry Standards

• The vesting schedule of 25% after one year and monthly thereafter for three years is a common industry practice for executive and director compensation in technology and healthcare companies, similar to vesting schedules observed at companies like Illumina or Exact Sciences.
• The conversion of restricted stock units at a $0 exercise price is standard for this type of equity award, reflecting the grant of full-value shares upon vesting.

Stakeholder Impact

• Shareholders: The vesting and conversion of RSUs for a director aligns the director's interests with long-term shareholder value.
• Employees: This transaction is part of a standard equity compensation framework, which can positively influence employee retention and motivation if similar plans are offered.

Next Steps

• The remaining 2,999 restricted stock units will continue to vest monthly over the remaining period of the three-year schedule following March 15, 2024.

Key Dates

Recommendation

This Form 4 filing details a routine vesting and conversion of restricted stock units by a director. It does not present new information that would fundamentally alter the investment thesis for Guardant Health, nor does it indicate any significant positive or negative operational or financial developments. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on existing company fundamentals rather than this specific insider transaction.

Keywords

Guardant Health, GH, Tariq Musa, Director, SEC Form 4, Restricted Stock Units, RSU, Stock Vesting, Insider Transaction